ili
ebola
viru
neg
sens
rna
genom
encod
differ
protein
surround
envelop
contain
viral
express
glycoprotein
gp
five
speci
ebola
viru
includ
zair
ebolaviru
sudan
ebolaviru
tai
forest
ebolaviru
bundibugyo
ebolaviru
reston
ebolaviru
name
place
first
discov
ebola
viru
gp
associ
viral
attach
host
cell
receptor
prior
viral
entri
cell
date
neutral
antibodi
target
ebola
viru
gp
report
somewhat
effect
reduc
sever
ebola
viru
infect
diseas
progress
anim
model
human
exampl
ebola
virusinfect
monkey
treat
within
hour
follow
ebola
viru
challeng
zmab
compos
three
monoclon
antibodi
mab
ebola
viru
gp
surviv
ebola
viru
infect
monkey
without
zmab
treatment
die
within
five
day
viral
infect
furthermor
zmapp
mapp
biopharmaceut
treatment
known
effect
reduc
mortal
rate
patient
infect
ebola
viru
despit
sever
ebola
viru
infect
current
neither
prevent
vaccin
therapeut
drug
readili
avail
use
thu
develop
vaccin
effect
drug
ebola
viral
infect
highli
demand
mab
broadli
util
medicin
well
diagnost
tool
viru
infect
mab
gener
hybridoma
technolog
mice
inject
immunogen
antigen
splenocyt
util
fuse
myeloma
cell
regard
antigen
high
puriti
nativ
protein
fold
prerequisit
gener
neutral
antibodi
target
nativ
form
viral
surfac
protein
dna
vaccin
thought
use
gener
nativ
viral
antigen
tend
express
protein
cell
manner
similar
real
viral
infect
howev
dna
vaccin
less
effect
produc
iggsecret
hybridoma
possibl
due
presenc
unmethyl
cpg
sequenc
dna
vaccin
stimul
polyclon
b
cell
activ
lee
et
al
studi
use
protein
boost
immun
effect
revers
prefer
product
igmsecret
hybridoma
iggsecret
hybridoma
moreov
multipl
immun
gp
gp
dna
vaccin
might
use
increas
chanc
gener
antibodi
higher
antigen
bind
affin
context
highli
like
appropri
applic
gp
dna
protein
vaccin
may
gener
hybridoma
clone
secret
igg
higher
bind
affin
nativ
form
antigen
studi
obtain
five
monoclon
igg
antibodi
immun
scheme
use
ebola
viru
gp
dna
protein
vaccin
antibodi
show
bind
activ
nativ
form
gp
express
cell
surfac
mucinlik
region
gp
denatur
form
gp
also
react
specif
gp
remain
reactiv
gp
lowest
test
concentr
rang
ngml
howev
none
antibodi
neutral
ebola
viru
infect
vitro
suggest
igg
antibodi
unabl
block
ebola
viru
infect
thu
igg
antibodi
possess
gpbind
activ
ebola
virusneutr
activ
sixweekold
femal
balbc
mice
purchas
daehan
biolink
eumseong
korea
mice
care
guidelin
kangwon
institut
anim
care
use
committeeapprov
protocol
cell
purchas
korean
cell
line
bank
seoul
korea
cell
human
embryon
kidney
cell
line
kindli
provid
jh
lee
kangwon
nation
univers
korea
cell
maintain
cdmem
media
dulbecco
modifi
eagl
medium
supplement
fetal
bovin
serum
fb
lglutamin
penicillinstreptomycin
gp
dna
vaccin
previous
test
encod
gp
zair
ebola
viru
strain
genbank
mammalian
cellderiv
recombin
gp
purchas
ybiolog
daejeon
korea
escherichia
colideriv
protein
previous
produc
test
cell
transfect
use
jetpei
transfect
reagent
polyplustransfect
inc
new
york
ny
usa
one
day
dna
transfect
cell
treat
concentr
intramuscular
im
electropor
ep
deliveri
dna
vaccin
mice
inject
intramuscularli
per
mous
final
volum
phosphatebuff
salin
pb
use
needl
inject
follow
ep
volt
second
use
cellectra
geneon
life
scienc
seoul
korea
accord
manufactur
protocol
plasmid
dna
produc
bacteria
purifi
use
endotoxinfre
qiagen
kit
accord
manufactur
protocol
qiagen
valencia
ca
usa
deliveri
recombin
gp
mice
inject
intraperiton
gp
per
mous
emulsifi
incomplet
freund
adjuv
mice
also
inject
intraven
recombin
gp
per
mous
final
volum
pb
mice
sacrif
day
last
inject
splenocyt
prepar
fusion
fusion
perform
previous
describ
briefli
splenocyt
cell
fuse
cell
use
polyethylen
glycol
cell
incub
day
cdmem
contain
hypoxanthineaminopterinthymidin
hat
subsequ
cell
incub
cdmem
contain
hypoxanthinethymidin
ht
day
cell
supernat
screen
absecret
hybridoma
use
enzymelink
immunosorb
assay
elisa
product
mab
absecret
hybridoma
dilut
make
less
singl
cell
per
well
use
limit
dilut
subcultur
method
hat
ht
purchas
sigmaaldrich
st
loui
mo
usa
hybridoma
cell
cultur
cdmem
contain
ht
cell
supernat
collect
use
purif
mab
mab
igg
purifi
use
protein
g
resin
column
accord
manufactur
protocol
peptron
daejon
korea
briefli
protein
g
resin
column
preequilibr
ml
bind
buffer
sodium
phosphat
buffer
nacl
ph
sampl
filter
filter
mix
equal
volum
bind
buffer
mix
sampl
load
onto
resin
column
follow
wash
ml
bind
buffer
final
bound
antibodi
elut
ad
elut
buffer
glycin
buffer
ph
particular
ml
elut
sampl
fraction
ad
neutral
buffer
trishcl
buffer
ph
adjust
ph
final
antibodi
dialyz
pb
well
well
plate
coat
overnight
recombin
gp
protein
pb
next
day
plate
wash
time
wash
buffer
tween
block
hour
block
buffer
wash
bovin
serum
albumin
plate
react
test
sampl
hour
plate
wash
time
wash
buffer
react
hour
horseradish
peroxidas
hrp
conjug
antimous
igg
h
heavi
l
light
dilut
block
buffer
wash
plate
abt
solut
merck
millipor
billerica
usa
ad
well
optic
densiti
od
read
nm
use
elisa
reader
particular
determin
rel
level
gpspecif
igg
subclass
hrpconjug
antimurin
antibodi
thermo
scientif
waltham
usa
substitut
hrpconjug
antimurin
igg
hl
hrpconjug
antimous
igg
hl
purchas
komabiotech
seoul
korea
hybridoma
cell
supernat
antibodi
sampl
separ
sdspolyacrylamid
gel
protein
gel
analyz
stain
brilliant
blue
r
stain
solut
elpisbiotech
daejon
korea
protein
also
electrophoret
transfer
immobilinp
membran
merck
millipor
membran
preequilibr
tbst
solut
mm
trishcl
ph
mm
nacl
tween
contain
skim
milk
hour
detect
antibodi
membran
incub
hrpconjug
antimous
igg
hl
komabiotech
hour
room
temperatur
step
membran
wash
time
tbst
immunoreact
protein
band
visual
use
ecl
detect
reagent
philekorea
seoul
korea
one
case
cell
lyst
separ
sdspolyacrylamid
gel
transblot
immobilinp
membran
membran
cut
mani
strip
react
purifi
igg
control
antiebola
viru
gp
commerci
antibodi
rais
rabbit
sino
biolog
beij
china
follow
incub
hrpconjug
antimous
igg
http
wwwecevrorg
http
hl
hrpconjug
antirabbit
igg
komabiotech
western
blot
assay
cell
react
minut
sera
purifi
igg
antibodi
fluorescenceactiv
cell
sort
fac
buffer
bovin
serum
albumin
follow
reaction
minut
fluorescein
isothiocyan
fitc
conjug
antimous
igg
whole
molecul
antimous
igg
fc
step
cell
wash
twice
fac
buffer
fitcconjug
antimous
igg
whole
molecul
antimous
igg
fc
purchas
sigmaaldrich
abcam
cambridg
uk
respect
final
cell
analyz
use
facscalibur
flow
cytomet
bd
bioscienc
san
diego
ca
usa
vero
cell
cultur
well
tissu
cultur
plate
follow
day
cell
approxi
cell
coloni
react
gpspecif
immun
sera
follow
reaction
fitcconjug
antimous
igg
whole
molecul
flow
cytometri
cell
measur
reactiv
gp
express
cell
b
cell
promin
react
antigp
sera
cultur
cell
lysat
run
sdspage
gel
transfer
nitrocellulos
membran
react
commerci
antigp
antibodi
western
blot
assay
c
mice
inject
imep
week
mice
bled
week
follow
final
inject
sera
collect
c
sera
react
control
cell
follow
incub
fitcconjug
antimous
igg
fc
flow
cytometri
gp
glycoprotein
fitc
fluorescein
isothiocyan
sdspage
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
im
intramuscular
ep
electropor
mate
confluent
antibodi
well
use
posit
control
neutral
serial
dilut
cdmem
equal
volum
ebola
viru
makona
genbank
ad
well
would
receiv
plaqu
form
unit
virusantibodi
mixtur
incub
hour
virusantibodi
mixtur
ad
incub
plate
hour
mixtur
remov
fb
dmem
ad
well
plate
return
incub
plate
read
cytopath
effect
postinfect
assay
perform
biosafeti
level
laboratori
nation
microbiolog
laboratori
part
public
health
agenc
canada
winnipeg
manitoba
canada
previous
report
gp
dna
vaccin
induc
agspecif
antibodi
respons
studi
investig
whether
gp
dna
vaccin
might
induc
igg
respons
nativ
form
gp
express
cell
surfac
therefor
cell
transfect
select
cell
six
cell
coloni
react
gpspecif
immun
sera
follow
flow
cytometri
use
fitcconjug
antimous
igg
whole
molecul
secondari
ab
fig
cell
display
promin
bind
reactiv
immun
sera
chosen
test
gp
express
statu
use
western
blot
assay
fig
seen
fig
display
kda
gp
band
oppos
control
cell
cell
design
next
immun
mice
imep
week
bled
week
sera
collect
react
cell
shown
fig
immun
sera
react
cell
cell
without
gp
express
flow
cytometri
use
fitcconjug
antimous
igg
fc
secondari
ab
result
show
gp
dna
vaccin
inde
induc
igg
antibodi
recogn
nativ
form
gp
express
cell
surfac
vivo
previous
report
dna
prime
protein
boost
preferenti
gener
hybridoma
secret
igg
antibodi
gener
igg
antibodi
higher
antigenbind
activ
immun
scheme
modifi
mice
inject
imep
week
follow
intraperiton
inject
week
recombin
gp
emulsifi
incomplet
freund
adjuv
four
week
later
mice
intraven
inject
recombin
gp
pb
mice
sacrif
day
final
inject
splenocyt
use
fusion
fusion
experi
hybridoma
cell
supernat
display
time
higher
od
valu
neg
control
elisa
display
heavi
light
chain
igg
western
blot
assay
select
data
includ
hybridoma
design
mab
product
select
hybridoma
dilut
make
singl
cell
clone
use
limit
dilut
subcultur
method
result
monoclon
clone
obtain
design
tabl
unfortun
unabl
gener
clone
secret
gpspecif
igg
antibodi
clone
addit
obtain
igmsecret
singl
clone
eg
hybridoma
final
igg
antibodi
purifi
cell
supernat
clone
use
protein
g
column
resolv
protein
band
h
chain
l
chain
sdspolyacrylamid
gel
fig
also
react
ebola
viru
gp
mer
coronavirusspik
protein
sft
viru
gp
determin
elisa
fig
result
suggest
purifi
igg
antibodi
inde
antigenspecif
furthermor
igg
antibodi
clone
remain
reactiv
gp
lowest
test
concentr
ngml
respect
fig
case
lowest
test
concentr
defin
lowest
igg
concentr
show
posit
optic
densiti
valu
compar
control
igg
igg
sampl
serial
dilut
dose
react
recombin
gp
elisa
igg
antibodi
five
clone
test
reactiv
five
differ
protein
igg
antibodi
clone
react
igg
antibodi
clone
fail
react
protein
fig
result
suggest
igg
antibodi
clone
may
recogn
either
tertiari
structur
gp
gp
region
exclud
receptorbind
domain
mucinlik
region
igg
antibodi
clone
might
recogn
mucinlik
region
gp
illustr
tabl
next
test
whether
igg
antibodi
clone
might
react
nativ
form
gp
express
surfac
cell
test
purifi
igg
react
cell
well
control
cell
without
gp
express
follow
flow
cytometri
shown
fig
igg
antibodi
clone
show
posit
reactiv
cell
cell
contrast
igg
antibodi
clone
display
reactiv
cell
result
suggest
igg
antibodi
clone
may
recogn
nativ
form
gp
express
cell
surfac
next
test
whether
igg
antibodi
clone
might
react
denatur
form
gp
shown
fig
neg
control
indic
ebola
viru
addit
alon
posit
control
indic
addit
ebola
viru
plu
igg
indic
cytopath
effect
indic
less
cytopath
effect
indic
zmab
cocktail
monoclon
igg
also
investig
whether
igg
antibodi
clone
might
possess
abil
neutral
ebola
viru
infect
shown
tabl
studi
observ
vaccin
dna
vaccin
encod
cell
membranetarget
viral
antigen
led
induct
igg
antibodi
recogn
nativ
form
antigen
express
cell
surfac
instanc
immun
sera
display
reactiv
gp
express
cell
surfac
demonstr
flow
cytometri
use
fitcconjug
igg
fc
fitcconjug
igg
whole
molecul
case
fitcconjug
igg
fc
recogn
igg
type
oppos
fitcconjug
igg
whole
molecul
data
includ
moreov
dna
vaccin
code
cell
membraneassoci
antigen
report
effect
induc
agspecif
immun
respons
compar
code
intracellular
antigen
data
includ
suggest
dna
vaccin
encod
viral
surfac
membran
protein
induc
igg
respons
nativ
outermembran
form
viral
protein
thu
possibl
igg
antibodi
may
util
target
viral
surfac
antigen
either
diagnost
neutral
antibodi
previous
report
dna
vaccin
alon
result
preferenti
product
igmsecret
hybridoma
iggsecret
hybridoma
studi
use
recombin
protein
dna
vaccin
platform
revers
propens
highlight
notion
protein
may
use
vaccin
type
increas
product
iggspecif
hybridoma
dna
vaccin
current
studi
success
gener
iggsecret
hybridoma
boost
gp
dna
vaccineprim
mice
gp
emulsifi
incomplet
freund
adjuv
final
gp
dissolv
pb
result
corrobor
notion
protein
booster
vaccin
type
may
play
critic
role
boost
product
iggsecret
hybridoma
dna
vaccin
platform
screen
scheme
use
elisa
western
blot
assay
abl
obtain
total
polyclon
hybridoma
secret
gpspecif
igg
type
among
obtain
five
clone
produc
igg
isotyp
two
clone
produc
igm
isotyp
limit
dilut
subcultur
method
purifi
monoclon
igg
antibodi
five
clone
react
ebola
viru
gp
mer
coronaviru
spike
protein
sft
virusgp
suggest
inde
antigenspecif
moreov
igg
kappa
type
remain
reactiv
ebola
viru
gp
lowest
concentr
rang
ngml
particular
igg
antibodi
clone
recogn
gp
express
cell
surfac
suggest
may
recogn
nativ
outermembran
form
gp
hand
igg
antibodi
one
clone
recogn
contain
mucinlik
region
alon
suggest
igg
antibodi
recogn
mucinlik
region
gp
howev
igg
antibodi
four
clone
recogn
none
http
wwwecevrorg
http
five
recombin
suggest
four
purifi
igg
antibodi
may
recogn
tertiari
form
gp
andor
gp
site
exclud
mucinlik
region
receptorbind
domain
gp
moreov
none
five
purifi
igg
antibodi
recogn
denatur
form
gp
data
line
observ
sera
anim
immun
gp
dna
vaccin
unabl
recogn
denatur
form
gp
western
blot
assay
data
includ
taken
togeth
data
show
five
purifi
igg
antibodi
recogn
nativ
gp
notabl
remain
five
polyclon
hybridoma
appear
lose
abil
produc
igg
antibodi
continu
cell
cultur
passag
lead
failur
make
igg
produc
among
numer
singl
clone
obtain
limit
dilut
subcultur
polyclon
hybridoma
singl
clone
observ
secret
agspecif
igg
antibodi
data
includ
context
highli
like
loss
igg
product
might
ascrib
decreas
fraction
iggproduc
hybridoma
cell
time
possibl
result
loss
chromosom
contain
gene
loci
igg
heavi
light
chain
support
previou
find
other
hand
clone
display
highest
od
valu
among
numer
clone
secret
igm
produc
prior
limit
dilut
subcultur
two
hybridoma
gener
igg
type
later
lost
abil
gener
igg
antibodi
like
case
hybridoma
iggproduc
cell
popul
may
disappear
replac
igmproduc
cell
popul
notion
support
observ
cell
supernat
two
hybridoma
exhibit
high
bind
activ
five
differ
recombin
suggest
antigennonspecif
bind
elisa
data
shown
addit
cell
supernat
also
react
gp
elisa
use
hrpconjug
igm
well
data
shown
confirm
clone
inde
polyclon
cell
produc
igg
igm
antibodi
report
ebola
viru
gp
respons
bind
host
cell
receptor
viral
entri
ebola
viru
gpspecif
antibodi
includ
monoclon
igg
antibodi
known
block
viral
infect
host
cell
studi
observ
five
purifi
igg
antibodi
unabl
block
ebola
viru
infect
host
cell
vitro
data
suggest
five
purifi
gpspecif
igg
antibodi
includ
three
recogn
nativ
gp
express
cell
surfac
neutral
activ
toward
ebola
viru
infect
summari
found
among
gpspecif
iggproduc
hybridoma
five
success
subclon
iggproduc
singl
clone
five
purifi
monoclon
igg
antibodi
recogn
gp
antigenspecif
igg
dosedepend
manner
particular
three
recogn
nativ
form
gp
express
cell
surfac
remain
reactiv
gp
lowest
test
concentr
rang
ngml
howev
antibodi
unabl
neutral
ebola
viru
suggest
none
purifi
antibodi
block
ebola
viru
infect
taken
togeth
five
purifi
igg
antibodi
possess
ebola
viru
gpbind
activ
ebola
viru
neutral
activ
